Page 4 - Penn Memory News Today

Cognitive decline makes people more vulnerable to financial mismanagement and exploitation. A growing body of research is clear — financial problems are not just a result of dementia, but can be a predictor.

Targeted News Service provides Washington Bureau coverage, federal contract and contracting information for awards and for subcontracting opportunities, a congressional vote chart, federal and congressional press releases.

Please join the Michigan Alzheimer’s Disease Center on Monday, Nov. 28 from 6 – 7:30 p.m. for a special event.  Jason Karlawish, M.D., professor of medicine at the Perelman School of Medicine at the University of Pennsylvania and director of the Penn Memory Center’s Outreach, Recruitment and Educ

A new training tool helps to assess whether some seniors can make informed choices about their own care and well-being.

Earlier this month, the Centers for Medicare and Medicaid Services announced it would cover the costs of a new Alzheimer’s drug. However, only if patients participate in clinical trials.The drug Aduhelm was approved last summer by the FDA. It was the first new Alzheimer’s drug approved since 2003.

Holiday family gatherings can be challenging under the best of circumstances.

Jul 12, 2021 As physicians and health policy experts debate the merits of Aduhelm, the first new drug for Alzheimer’s disease approved in 18 years, patients want to know: “Will this medication help me — and how much?” Doctors explaining the pros and cons of Aduhelm won’t have a definitive answer. “On an individual basis, it will be absolutely impossible to predict,” said Dr. Allan Levey, director of the Goizueta Alzheimer’s Disease Research Center at Emory University. Cognitive...

Matt York/AP toggle caption Matt York/AP Dr. William Burke reviews a PET brain scan at Banner Alzheimers Institute in Phoenix in 2018. An experimental Alzheimers drug from Biogen and Eisai is on the verge of a Food and Drug Administration decision. Matt York/AP A drug called aducanumab could become the first approved treatment designed to alter the course of Alzheimers disease rather than relieve symptoms. But its unclear whether the Food and Drug Adminis...

The FDA has until Monday to decide whether to approve the first new Alzheimers drug in nearly two decades. Two big studies of the drug produced conflicting results.

The problem of Alzheimer’s: Caregiver exhaustion and a minefield of ethical quandaries As the worlds population ages, a new generation will be facing Alzheimers. A new book delves into the diseases toll and whats needed to quell the effects of the coming wave. (Getty Images) It’s hard to find good news about Alzheimer’s disease. The dementia math has been pitiless for decades, especially as it applies to Alzheimer’s, which accounts for up to three-quarters of dementia cases. All over ...